GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
Meanwhile, their presentation is being accompanied by significant sells!
One wonders how long the company’s lack of real progress will continue? Surely they are not going to waste more time in presenting at conferences this coming season? High time for them to roll up their sleeves and get on with some real work!
Additionally, it is probably the right time for the 2021 hires, in anticipation of commercialisation in 2022, to leave the stage? Enough is enough!
Rant over!
Attendees at today’s AGM are being given a presentation on stratified medicine by Prof Sir Stephen Holgate, and Dr. Monk. The slides are displayed on the Synairgen website.
At the very end, they state that they are preparing to commence the trials ‘this coming Winter’! As one of the most cynical contributors to this forum, I am getting a sense of deja vu from that last phrase! I trust that something will actually happen this time around? Our friends at the AGM will no doubt gauge the sentiment of the Synairgen team, and share with us later.
GLALTIs.
It didn’t have anything to do with your rebuttal Docdaneeka. It was hold4results’ third post, which contained a crude sexual reference, that probably did it? When it was removed, your contribution, the next one in the thread, was also deleted.
The right outlets for hold4results’ disjointed ramblings probably exist somewhere in cyberspace? This forum is not one of them IMHO.
Well argued! A similar comment, but from a different angle, was offered on the bulletin board of a different company. It might equally apply to Synairgen?
“For the post Covid scenario in this sector, revenue trumps outstanding science and opportunity. Perhaps PI investment is now less speculative? This will turn again in time.”
GLA for tomorrow. In particular, to investors attending the AGM. I wish you all a good day, and a positive experience. Any feedback would be gratefully accepted.
"We are now working IN HASTE on discussions with platform trial organisers and investigators, as well as regulatory authorities, the pharmaceutical and biotech industry and government bodies to identify and establish the optimal method of conducting further trials to confirm these findings and move forward, not just for COVID-19, but also as a potential treatment for patients hospitalised due to a range of viruses including influenza, RSV, adenovirus, para-influenza and rhinoviruses."
Richard Marsden. 25 May, 2022.
Should it have taken until some, as yet unannounced , time during H2, 2023 for any form of trial activity to commence?
The possibility of an RNS emerging prior to the AGM is very slim, unless there is game changing news afoot?
There have been two RNS statements with information to investors in the last seven months.
Last December brought the summative paper, listing the Sprinter trial outcomes. Investors were well versed on that information beforehand.
Subsequently, two months ago we received the 2022 end of year statement. This signalled the end of the “partnership” trial negotiations that we were implicitly led to believe were underway? Instead we were introduced to the small scale company trialling, which will commence sometime during H2. Apparently, these are intended to provide further information towards identifying an appropriate cohort for a future Phase III trial of our host directed, broad spectrum antiviral agent? The time scale and funding of this potential trial are as yet unclear. Perhaps the consortium mentioned by Ghia are waiting in the wings to help out?
I expect that the CEO and his team will expand on the latter in the vaguest possible terms during tomorrow’s Q&A session? Isn’t this what they did last year, only to cancel their “strategy” ten months later?
My sincere gratitude to all Synairgen investors who are able to attend, and effectively represent this forum, in tomorrow’s AGM meeting. I hope that the company have more to communicate than the scraps of information that they have fed investors for sixteen months.
It is best to allow realism to dictate to our aspirations as the AGM approaches. My previous negative comment reflects my disappointment with this company’s abject failure to advance on their aspirations over the last year.
Yesterday, TommyD_19 painted a realistic picture as to what the next year might hold. Synairgen are retreating into the university spin-off space (their comfort zone), and unless an unforeseen development materialises, this is where they will remain for the time being. The share price will probably further decline as a result.
On the positive side, TFG’s 28.2% holding remains intact. A ray of sunshine on an otherwise bleak landscape.
GLALTIs.
Excellent news from the company this morning.
Additionally, given another headline today, this appears to be a good space to be invested in at the present time.
Given the right alignment, this investment should produce several multiples of the current share price. More, should a large entity swoop in!
https://www.bbc.co.uk/news/health-65988768
“I’m still not convinced they’ll be a Q&A or some excuse to cut it short”
Doc 83.
I have had serious doubts about the abilities, and attitudes towards investors, of the company’s executives for some time. They are well behind what I would deem to be a reasonable time frame to make some progress in getting their product to another trial. Sixteen months of jam tomorrow statements without measurable development is underwhelming to say the least.
Recently, I was in a toy shop with our youngest family member. When he was offered a Buzz Lightyear toy (on 60% discount) as an extra gift, he immediately declined. When asked “Why not?” he replied “Not cool!”. I have a similar sentiments about Synairgen’s version of the Pixar superhero.
Synairgen’s AGM onThursday 29 is not included in London South East’s long list* of AGMs scheduled for the coming week? This is most probably an oversight on the part of LSE?
* From LSE’s ‘Week ahead’ newsletter received yesterday evening.
TommyD_19.
All investors will agree with you about these most pressing issues. We have patiently waited for a significant update since the last AGM. As yet this hasn’t materialised, although the goalposts have since been shifted.
Achieving targeted data leading to a Phase III trial is now the company’s primary aim, and should command their exclusive focus?
It is therefore disconcerting that in the absence of progress, the board have issued a resolution for additional retrospective remuneration? It is not the amount that I question, but the priorities of the BOD and the message that it sends to investors?
Mr. Shaw holds a significant shareholding in Synairgen. Should the company progress towards bringing SNG001 to market, he will be amply rewarded, as will all Synairgen investors. I sincerely hope that we will receive some indication that progress is being made during the next week.
Synairgen’s Chairman currently has eleven active directorships , in addition to his day job as Savills’ CFO. His latest appointment in 2022 is with a company in the software development space. He has maintained his Synairgen Chairman role for two decades.
How can anyone with his fingers in so many pies justify asking for a stipend of £85K p.a. from a small struggling pharmaceutical company? The same question could be put to the other directors, in particular the three overpaid Synairgen executives? Someone mentioned something about it being a suitable payment for “World class” directors? Surely no one in Synairgen’s boardroom merits that description?
https://find-and-update.company-information.service.gov.uk/officers/dNimElwmaD2JNgfjP6gnKrNKZbk/appointments
I agree with Docdaneeka that if there is nothing new and significant added at the AGM, serious questions need to be asked about how this business is being run?
GLALTIs.
The directors’ budget is £200K - an average of £25K p.a. for each director. Three of the directors are also the company’s three most senior executives, each with a salary and other remunerations package in excess of £350K. (I have based this on online sources, please feel free to correct me, if appropriate).
None of these individuals has merited a pay increase. If there has been an overspend in the budget, perhaps it should be absorbed from next year’s budget?
The company hasn’t earned any money. It remains in existence solely from a shareholder capital raise for their previous trial.
The company needs to be more prudent with our money, until it becomes self financing IMHO.
B2HS2L
My guesstimate share price range was based on the interim values achieved during the company’s previous upward trajectory to a funded Phase III trial.
Should the company demonstrate similar progress in the future, their return to credibility will be acknowledged by the market.
Should this prove to be the case, I doubt whether they will receive the backing of investors, as before? The trial would need to be funded by a different ‘vehicle’, or another solution to bring the product to market would need to be found?
Thank you Lurker2020.
The AGM is all about the reappointment of directors, and approving a 75% increase in their annual remuneration pot. Simon Shaw justifies the increase as being less than the net increase in RPI since 2004. A pompous statement from a chairman who doesn’t acknowledge the fact that, for the time being, all of Synairgen’s expenses are derived from the residue of the shareholder capital invested in their SNG0018 trial.
I will stick with my cart and horse analogy. Why not wait for the company to deliver a clinical outcome to significantly increase the share price first? A share price increase, to 40-50p say, would get Synairgen back on track. It would be more appropriate for the company to submit a claim for additional director remuneration, and share options for executives when they actually deliver a “concrete” outcome to investors.
My personal thanks 🙏 to all of you attending the AGM. If there is a Q&A session at the end, I hope that the answers will offer more insight than the jam tomorrow statements offered by the CEO last time around.
GLALTIs.
Apparently the LSE formatting tool introduced a “.” at the end of the link. Here it is again:
https://rb.gy/v2k1q
Apparently life has started to go on at Synairgen Research following the departure of Brooke Clarke. The following appeared on LinkedIn about 1h ago.
I admired the Synairgen corporate image that Mrs. Clarke had consistently repeated in the twitter/LinkedIn carousel. That has disappeared. The link just leads to the first page of the website. Vin ordinaire at best.
“For #Media #Investors
“It’s Love Your Lungs Week in the UK! According to Asthma + Lung UK, 1 in every 5 people will have a lung condition in their lifetime and 5.4 million people in the UK are currently living with asthma. Our lungs are vital for a healthy and active life.
Understanding how and why some people’s lungs are unable to defend themselves has been at the heart of the Synairgen story from the beginning.
Learn more: https://rb.gy/v2k1q. ”
Aether, you really should have worked out who that is, as you have given him an unflattering mention on many occasions.
Spacman’s valued contribution to our debate has never evoked the negativity of that individual, who has made more comebacks than Frank Sinatra!
He is trying his best to remain hidden in plain sight, but not succeeding! Anyhow, why am I bothering to give him more of the oxygen that he craves?
Last year, Brooke Clarke was granted share options. Helen Gearing was not. From today’s update, we can conclude that Brooke Clarke has not been granted any options. Presumably, this is because she has left the company? Other than this nothing else about the process has changed, other than the magnitude of the awards.
Other than stating that this is the company’s process, can the CEO defend these awards to investors if questioned next week? Surely the answer to that question is no. Today’s grant of options has not been earned, as the company has offered nothing concrete to investors in 16 months. We all want that situation to change. Let us see if there is an update in the run up to the AGM. The CEO and his execs have disappointed investors for well over a year, so I shan’t hold my breath.
https://www.londonstockexchange.com/news-article/SNG/grant-of-options/15527414
GLALTIs.
Jody Brookes and Richard Francis are SVPs. They have been granted options.